<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:subject xml:lang="eng">Leukaemia</dc:subject>
  <dc:subject xml:lang="eng">Targeted Therapies</dc:subject>
  <dc:subject xml:lang="eng">Translational Research</dc:subject>
  <dc:description xml:lang="eng">T-prolymphocytic leukemia (T-PLL) is a rare, aggressive T-cell malignancy with poor outcomes and an urgent need for new therapeutic approaches. Integrating genomic data and new transcriptomic profiling, we identified recurrent JAK/STAT mutations (predominantly in JAK3 and STAT5B) as hallmarks in a cohort of 335 T-PLL cases. In line, transcriptomic and protein analyses revealed constitutive JAK/STAT activation in virtually all samples. Consequently, we explored the anti-leukemic potential of dual STAT3/STAT5 non-PROTAC degraders in T-PLL, with JPX-1244 as our lead substance. JPX-1244 efficiently and selectively induced cell death in primary T-PLL samples, including those resistant to conventional therapies, by blocking STAT3 and STAT5 phosphorylation and by inducing their degradation. The extent of STAT3/STAT5 degradation directly correlated with cytotoxicity. RNA-sequencing confirmed the treatment-related downregulation of STAT5 target genes. While JAK/STAT mutations did not predict responses to pharmacologic STAT3/STAT5 degradation, elevated expression of TOX, PAK6, and SPINT1 were associated with drug sensitivity. In subsequent combination screenings, cladribine, venetoclax, and azacytidine emerged as most effective combination partners of STAT3/STAT5 degraders, even in low-responding T-PLL samples, all synergistically reducing STAT5 phosphorylation. These findings highlight dual STAT3/STAT5 inhibition, particularly in combination with hypomethylating and BCL2-targeting agents, as a promising interventional approach in T-PLL, warranting further investigation.</dc:description>
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:format>application/pdf</dc:format>
  <dc:source xml:lang="eng">Leukemia</dc:source>
  <dc:title xml:lang="eng">Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia</dc:title>
  <dc:date>2025</dc:date>
  <dc:publisher>Nature Publishing Group</dc:publisher>
  <dc:rights xml:lang="eng">Copyright © 2025, The Author(s)</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:type xml:lang="ita">Testo</dc:type>
  <dc:type xml:lang="ita">Articolo di rivista</dc:type>
  <dc:language>eng</dc:language>
  <dc:creator>Annika Dechow</dc:creator>
  <dc:creator>Sanna Timonen</dc:creator>
  <dc:creator>Aleksandr Ianevski</dc:creator>
  <dc:creator>Qu Jiang</dc:creator>
  <dc:creator>Linus Wahnschaffe</dc:creator>
  <dc:creator>Yayi Peng</dc:creator>
  <dc:creator>Dennis Jungherz</dc:creator>
  <dc:creator>Kerstin Becker</dc:creator>
  <dc:creator>Heidi Neubauer</dc:creator>
  <dc:creator>Susann Schoenefeldt</dc:creator>
  <dc:creator>Elvin D. de Araujo</dc:creator>
  <dc:creator>P. Gunning</dc:creator>
  <dc:creator>Roman Fleck</dc:creator>
  <dc:creator>Alexandra Schrader</dc:creator>
  <dc:creator>Michael Hallek</dc:creator>
  <dc:creator>Natali Pflug</dc:creator>
  <dc:creator>Richard Moriggl</dc:creator>
  <dc:creator>Tero Aittokallio</dc:creator>
  <dc:creator>Satu Mustjoki</dc:creator>
  <dc:creator>Till Braun</dc:creator>
  <dc:creator>Marco Herling</dc:creator>
  <dc:identifier>doi:10.1038/s41375-025-02577-8</dc:identifier>
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:4646</dc:identifier>
</oai_dc:dc>